CONGRESS ABSTRACT

Background: immune-checkpoint inhibitors (ICIs), such as Pembrolizumab (a PD-1 monoclonal antibody), have revolutionized cancer therapy. These drugs stimulate T-cell response against the tumor, but due to activation of the immune system, their use can cause immune-related adverse events that may involve the myocardium, leading to the development of fulminant…

Myocarditis associated with immune checkpoint inhibitors (ICIs) is a rare complication but carries a high mortality rate. The clinical presentation can mimic acute coronary syndrome, making diagnosis complex and often delayed.An 81-year-old man was admitted to the emergency department with worsening dyspnea. The ECG showed lateral ST-segment elevation associated…

The Triple-M Syndrome is a rare and severe immune-mediated adverse event associated with Immune Checkpoint Inhibitors, characterized by the concomitant occurrence of myocarditis, myositis, and myasthenia gravis. To date, approximately 50 cases have been reported, mainly following pembrolizumab or nivolumab administration in patients with melanoma, lung, or renal cancer,…

Ulcerative colitis (UC) is primarily a gastrointestinal disorder, but 25–40% of patients may develop extraintestinal manifestations. Cardiac involvement is rare (<1%), with pericarditis and, more infrequently, myocarditis. Mesalazine is a common first-line therapy for mild-to-moderate UC and is generally well tolerated, though rare cases of drug-induced myopericarditis have been…

Immune checkpoint inhibitors (ICIs) are increasingly used in oncology but may cause severe immune-related adverse events, including myocarditis, a rare condition associated with high mortality. Predominant right ventricular (RV) involvement and overlap with neuromuscular toxicity represent an exceptionally uncommon and aggressive presentation. We report the case of a 68-year-old…

Introduction: Mesalazine (5-ASA) is a cornerstone therapy for ulcerative colitis (UC), but rarely can cause immune-mediated cardiotoxicity (myocarditis/pericarditis/myopericarditis), usually within weeks of starting induction. CMR is pivotal to confirm myocardial/pericardial involvement and guide follow-up. Case: A 28-year-old man with UC presented with acute pericarditic chest pain (worse supine/deep inspiration,…

Background Mesalazine (5-aminosalicylic acid) is a first-line therapy for ulcerative colitis. Cardiac inflammation, including myocarditis and pericarditis, represents a rare but potentially serious adverse effect and may be difficult to distinguish from extraintestinal manifestations of inflammatory bowel disease. Case presentation A 20-year-old man with a recent diagnosis of ulcerative…